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abstract: Objectives: Prostate cancer is a leading cause of cancer-related deaths. The number of deaths and 
years of life lost (YLL) due to a disease can be used to monitor health status, assess healthcare needs and determine 
the prioritisation and allocation of health resources within a population; in addition, the latter calculation can 
serve as a baseline indicator of premature mortality. This study aimed to measure prostate cancer-related mortality 
and YLL in Yazd Province, Iran. Methods: This study included all prostate cancer-related deaths in Yazd Province 
reported between March 2001 and March 2010. Mortality data were obtained from a provincial death registration 
system which integrates data from different sources. YLL was calculated based on an individual’s age at death and 
their life expectancy according to age group. Results: During the study period, prostate cancer was the fourth most 
common fatal cancer among men, resulting in 324 deaths or 10.0% of all cancer-related deaths. The crude mortality 
rate per 100,000 individuals increased from 4.7 in 2001 to 8.8 in 2010. Premature deaths caused 1,358.7 YLL and 
the YLL caused by prostate cancer deaths more than doubled from 94.7 in 2001 to 196.5 in 2010. Conclusion: Due 
to changes in population structure, it is likely that the burden of prostate cancer will continue to increase in Yazd 
Province. As such, it is necessary that the national health system implements screening programmes and improves 
public awareness of prostate cancer-associated risk factors.
Keywords: Prostate Cancer; Years of Potential Life Lost; Mortality; Health Status Indicators; Iran.
التي  اأعداد املتوفني به، وال�صنوات  ا�صتخدام  اآثار ال�رشطان. وميكن  الوفاة من  اأ�صباب  اأهم  الهدف: يعد �رشطان الربو�صتاتة من  امللخ�ص: 
الأولويات، وتخ�صي�ض  ال�صحية، وحتديد  الرعاية  احتياجات  ال�صحية، وتقييم  ب�صبب ذلك املر�ض يف ر�صد احلالة  اأعمارهم  �صاعت من 
للقيمة  املر�صى كموؤ�رش  التي �صاعت من عمر  ال�صنوات  ت�صتخدم ح�صابات  اأن  لذلك ميكن  وبال�صافة  لل�صكان يف منطقة معينة.  املوارد 
يف  الربو�صتاتة  �رشطان  ب�صبب  ال�صائعة  ال�صنوات  وعدد  الوفيات  معدل  لقيا�ض  الدرا�صة  هذه  وهدفت  املبت�رشة.  الوفيات  ملعدل  القاعدية 
2010. وحت�صلنا  2001 ومار�ض  الدرا�صة كل مر�صى �رشطان الربو�صتاتة مبحافظة يزد بني مار�ض  الطريقة: �صملت  حمافظة يزد باإيران. 
على اأعداد املتوفني باملر�ض من �صجالت املوتى مبحافظة يزد، والتي جتمع من م�صادر خمتلفة. ومت ح�صاب عدد ال�صنوات ال�صائعة ب�صبب 
املر�ض بناءا على عمر املري�ض عند الوفاة، وماأمول احلياة بح�صب املجموعة العمرية التي يقع فيها. النتائج: كان �رشطان الربو�صتاتة يف 
غ�صون �صنوات البحث هو الرابع بني اأنواع ال�رشطانات القاتلة، فقد ت�صبب يف وفاة 324 مري�صا، اأي %10.0 من كل الوفيات ب�صبب اأنواع 
2010. وت�صبب املوت املبت�رش  2001 اإىل 8.8 يف عام  100,000 �صخ�ض يف عام  4.7 لكل  الوفيات من  ال�رشطانات املختلفة. وزاد معدل 
يف �صياع 1,358.7 �صنة. اأما �رشطان الربو�صتاتة فقد �صبب �صياع �صنوات من اأعمار املر�صى بلغت 94.7 يف عام 2001، وت�صاعفت يف 
عام 2010 اإىل 196.5. اخلال�صة: يتوقع زيادة عبء �رشطان الربو�صتاتة يف حمافظة يزد ب�صبب التغيريات يف تركيبة ال�صكان. ولهذا من 
ال�رشوري اأن يطبق النظام ال�صحي القومي برامج مل�صح وحتري املر�ض بني ال�صكان، واأن يح�صن من وعيهم بعوامل الختطار املرتبطة 
ب�رشطان الربو�صتاتة.
الكلمات املفتاحية: �رشطان الربو�صتاتة؛ �صنوات احلياة املحتملة املفقودة؛ الوفيات؛ موؤ�رشات احلالة ال�صحية؛ اإيران.
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Advances in Knowledge
- This study found that both the prostate cancer-related mortality rate and years of life lost due to prostate cancer increased over a 10-year 
period in Yazd Province, Iran. 
Application to Patient Care
- The findings of this study have implications for modifying on-going cancer screening programmes, prioritising health interven- 
tion programmes and integrating prostate cancer screening within the national health system in Iran.
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Cancer is a leading cause of mortality and years of life lost (YLL) worldwide; by 2050, the incidence of cancer in developing 
countries is forecast to increase by 45%.1 Due to the 
high fatality rate of most cancers, YLL account for 90% 
of the burden of the disease and can therefore help 
policy-makers to prioritise health problems and design 
health interventions.2–4 The calculation of trends in 
cause-specific mortality can also help to indicate the 
effectiveness of healthcare programmes and the role 
of environmental risk factors in disease incidence and 
management.5
In 2012, approximately 1.1 million men worldwide 
were diagnosed with prostate cancer, making it the 
second most common cancer among men, equivalent 
to 15% of all male cancers.6 The incidence of this 
disease varies widely by geographical region, from 4.5 
and 10.5 cases per 100,000 individuals in South Central 
and Eastern Asia, respectively, to 111.6 cases per 
100,000 individuals in New Zealand and Australia.6 Of 
all new cases of prostate cancer in 2012, approximately 
70% were reported from developed countries.6,7 Apart 
from the role of screening, this variation may be 
due to lifestyle, dietary, environmental and genetic 
differences.8 Nevertheless, while prostate cancer mort- 
ality in Western countries has reduced due to early 
diagnosis and treatment, the burden of prostate cancer 
is still growing in many developing countries, including 
Iran.9–14
In Iran, cancer is the third leading cause of 
mortality after cardiovascular disease and accidents, 
while prostate cancer is the third most common cancer 
and the eighth leading cause of mortality.13 However, 
trends in prostate cancer-related mortality have not 
been reliably measured in different regions within the 
country. Therefore, this study aimed to determine the 
burden and trends of prostate cancer-related mortality 
over a 10-year period in Yazd Province, a region at 
the geographic centre of Iran. In addition, the impact 
of premature deaths due to prostate cancer was 
quantified by calculating YLL due to the disease.
Methods
This study included all deaths due to malignant 
neoplasms of the prostate reported in Yazd Province 
between March 2001 and March 2010. Mortality data 
were obtained from the national death registration 
system in Iran which consists of information reported 
by physicians, healthcare institutions and cemeteries. 
Trained physicians at various institutions in Iran 
first report and code causes of death according to 
national protocols and the International Classification 
of Diseases; thereafter, hospitals, local health centres 
and cemeteries report these data monthly to a 
death registry committee.15 These reports are then 
matched and compared with data from the National 
Organization for Civil Registration and the Forensic 
Medicine Department. For the purposes of the study, 
duplicate death reports as determined based on 
similarities in the names of fathers, times of death and 
national identification numbers were excluded. When 
a garbage code or incomplete report was found, the 
researchers tried to retrieve the correct information 
via telephone interview with the responsible physician. 
This protocol was similarly used to obtain data for 
other causes of death.
Total population estimates in Yazd Province 
were calculated using information from health centre 
databases and national census data from 1996–2011 
for which annual population growth was estimated 
exponentially.16 As such, the population of Yazd Prov-
ince was set at 900,964 in 2001 and 1,056,638 in 2010, 
with the proportion of elderly individuals increasing 
from 8.3% to 9.1%, respectively. Estimated demographic 
data for each year were used to calculate the indices for 
that specific year. Subsequently, the mortality rate from 
prostate cancer per 100,000 individuals, percentage of 
prostate cancer deaths out of all cancer deaths and YLL 
due to prostate cancer were calculated. The formula 
used to calculate YLL was determined as follows:17,18 
where N is the number of deaths within a certain age 
group and gender, L is the standard life expectancy of 
the deceased according to age group and gender, r is 
a discount rate of 0.03, β is an age weight of 0.04, C is 
an age weight correction factor of 0.165, a is the age at 
death and e is Euler’s constant which is approximately 
equal to 2.71828. The average YLL (AYLL), which indi- 
cates how many more years a person would have 
lived had they not died prematurely, was calculated by 
dividing the total YLL by the total number of prostate 
cancer deaths annually.
Analysis of the data was performed using a YLL 
template developed by the World Health Organization 
in an Excel spreadsheet, Version 2007 (Microsoft 
Corp., Redmond, Washington, USA).17 A Chi-squared 
test was used to compare annual mortality rates. A 
P value of <0.05 was considered statistically significant. 
The protocol of this study was reviewed and approved 
by the Ethics Committee of the Shahid Sadoughi 
University of Medical Sciences, Yazd Province. All 
aspects of the study were conducted in accordance 
with the ethical codes of the university and only anony-
mous secondary data were utilised for the analysis. 
YLL = N Ce(ra)/(β + r)2 [e-(β + r) (L + a)[- (β + r) 
(L + a) -1] - e-(β + r) a [- (β + r) a-1]]
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Results
According to mortality data, a total of 324 deaths due 
to prostate cancer were reported in Yazd Province 
between 2001 and 2010. Prostate cancer was the fourth 
leading fatal cancer among men [Figure 1], accounting 
for 10.0% of all male cancer-related deaths. The total 
number of annual deaths due to prostate cancer 
increased significantly over the 10-year study period 
(P <0.05) [Figure 2]. The mean age of the victims was 
78 years (95% confidence interval: 77–79 years) and 
mean age did not differ significantly according to year 
(P >0.05). The majority of deaths occurred among men 
aged 70 years or older (87.7%) [Table 1], although the 
youngest victim was only 33 years old. The mortality 
rate per 100,000 individuals increased from 4.7 in 2001 
to 8.8 in 2010. The total YLL was 1,358.7 years and 
the overall AYLL was 4.2 years over the study period. 
The annual YLL more than doubled during the study 
period from 94.7 years in 2001 to 196.5 years in 2010 
[Table 2].
Discussion
In the current study, the prostate cancer-related 
mortality rate per 100,000 individuals in Yazd Province 
increased from 4.7 in 2001 to 8.8 in 2010. A similar 
increasing trend has been reported in another study 
from Iran, although the annual mortality rates were 
comparatively lower (0.63 in 1995 to 5.49 in 2004).19 
This difference highlights the likelihood of regional 
differences within the country with regards to the 
incidence and mortality of this type of cancer.13,19–21 
Research conducted in other Iranian provinces has 
also shown wide variation in the incidence of prostate 
cancer, ranging from 3.2 to 16.0 cases per 100,000 
individuals.22 Furthermore, the incidence of prostate 
cancer directly correlates with age and is rarely 
diagnosed among men under 50 years old; as such, 
the rate of mortality due to prostate cancer increases 
correspondingly with age.23 As a higher percentage of 
the population in Yazd Province is elderly in comp-
arison to the rest of Iran, this may also explain the 
higher incidence and mortality rates observed in the 
current study.24 In general, YLL due to prostate cancer 
are lower on average compared to other cancers; 
however, within elderly populations, prostate cancer 
significantly contributes to total YLL.4 
Currently, the incidence of prostate cancer 
remains higher in developed rather than developing 
countries.14 Nevertheless, although prostate cancer-
related mortality varies widely throughout the world, 
there is an increasing trend in prostate cancer-related 
mortality in less developed countries in contrast to 
Western countries.14 In 2012, prostate cancer-related 
mortality rates in Asian countries ranged from 0.7 
and 1.2 per 100,000 individuals in Bhutan and Nepal 
to 17.1 and 22.8 per 100,000 individuals in Turkey 
and Lebanon, respectively.7 In Iran, the prostate 
cancer-related mortality rate has been reported to 
be 6 per 100,000 individuals.13 Differences in mort-
ality between various countries, specifically in comp-
arison to incidence, may be due to variations in the 
implementation of screening programmes and the 
availability of better diagnostic resources and treatment 
facilities.25 In addition, the effect of ethnic and genetic 
Figure 1: The ten leading causes of male cancer-related 
deaths between 2001–2010 in Yazd Province, Iran 
(N = 2,669).
CNS = central nervous system.
Figure 2: Trend in the number of prostate cancer-related 
deaths among deaths reported between 2001–2010 in 
Yazd Province, Iran (N = 324).
Table 1: Prostate cancer-related mortality by age group 
among deaths reported between 2001–2010 in Yazd 










30–49 2 0.2 0.5
50–59 12 3.7 3.2
60–69 26 12.4 4.6
70–79 133 87.0 13.6
≥80 151 249.5 21.8
*Percentage of prostate cancer deaths out of all cancer deaths.
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variations on the incidence of prostate cancer has not 
yet been well determined.26,27 These variations may 
explain differences in the rate of deaths reported in 
Yazd Province as compared to other regions in Iran.
In the current study, the majority of deaths 
from prostate cancer occurred among those aged 
70 years or older, which is consistent with the findings 
of other studies worldwide, indicating that age is 
one of the most important risk factors for prostate 
cancer.28,29 After the age of 50 years old, the lifetime 
risk of developing evidence of histological prostate 
cancer-related changes is estimated to be 42%.28 
Moreover, according to research performed on autopsy 
samples, the prevalence of prostate cancer doubles 
approximately every 14 years.29 The combined effect 
of increased life expectancy and a growing elderly 
population underscores the importance of manage-
ment strategies for prevalent diseases such as prostate 
cancer. Therefore, the increasing rate of prostate 
cancer-related mortality in Iran can be prevented 
through the development of additional screening 
programmes targeting the elderly in order to provide 
early diagnosis and care, specifically in provinces with 
a higher percentage of elderly and middle-aged people. 
Nevertheless, it is possible that a greater number 
of younger people may be diagnosed with prostate 
cancer if they are provided with easier access to 
screening and diagnostic tests. Both lifestyle and 
dietary habits play a role in the pathogenesis of prostate 
cancer.30 A diet rich in red meat and smoking are risk 
factors for prostate cancer, whereas the consumption 
of tomatoes and participating in physical activity are 
potential preventative factors.31,32 A previous study 
found that 75.7% of elderly men in Yazd Province 
consumed red meat twice or more per week and 
28.2% engaged only in low levels of physical activity; 
this may therefore explain the higher than average 
rates of prostate cancer in Yazd Province.33 However, 
establishing a definitive correlation between these 
factors would require further and more specific 
research. 
The reported incidence and prevalence of prostate 
cancer is directly correlated with diagnostic measures; 
as such, the number of undiagnosed and non-reported 
cases should be considered when comparing prostate 
cancer incidence, prevalence and mortality rates. 
For example, many elderly individuals may die from 
other causes before showing signs of prostate 
cancer.34 Moreover, in addition to the introduction of 
the prostate-specific antigen (PSA) test, other changes 
in diagnostic and therapeutic methods may play a 
role in observed variations in prostate cancer inci-
dence. Accordingly, rises in the diagnosis of prostate 
cancer have been linked to greater use of transurethral 
resections for benign prostate hyperplasia (BPH), 
as the surgery involves sampling and pathological 
assessment of the prostate. On the other hand, 
the use of α-blockers and 5-α-reductase for BPH 
treatment decreases the frequency of tissue sampling 
and may subsequently cause a reduction in reported 
incidence rates.35 Researchers disagree about the 
effectiveness of PSA screening in reducing prostate 
cancer-related mortality rates; while some studies 
propose this test as a noninvasive, easy-to-use, early 
screening tool in the general population, other studies 
have recommended PSA testing only for those at a 
high risk for the disease.36–38 An algorithm has been 
suggested to identify high-risk patients based on their 
family history, digital rectal examination results and 
ethnicity.39
In the current study, while the overall mortality 
trend was found to have increased over the study 
period, there was a reduction in certain years, 
perhaps due to inconsistencies in the data collection. 
Temporarily rising trends may be due to the improved 
reporting and registration of deaths. Unfortunately, 
the specific diagnostic and treatment modalities 
offered to the patients involved in the current study 
prior to their deaths were not investigated. Therefore, 
further studies are required to determine whether the 
increased mortality was treatment-related or due to a 
lack of comprehensive screening. The current study 
Table 2: Mortality and years of life lost due to prostate cancer among deaths reported between 2001–2010 in Yazd 
Province, Iran (N = 324)
2001 2002 2003 2004 2005 2006 2007 2008 2009 2010
Number of deaths 22 19 24 36 25 38 39 31 42 48
Mortality rate per 
100,000 individuals
4.7 4.0 4.9 7.3 5.0 7.3 7.5 5.9 7.8 8.8
YLL 94.7 68 102.6 159.1 115.1 172.8 133.6 133.4 182.9 196.5
Percentage* 9.6 7.6 8.7 11.4 7.7 11.5 9.8 8.6 10.8 13.0
YLL = years of life lost.
*Percentage of prostate cancer deaths out of all cancer deaths.
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was also subject to other limitations. First, the data 
obtained originated from a death registry based on 
death records, so the effect of spatial and temporal 
variations in diagnostic approaches on the incidence 
of prostate cancer was not evaluated. Second, tele-
phone interviews with responsible physicians were 
undertaken only in cases of missing data or garbage 
codes. Thus, the researchers were unable to determine 
potential mistakes in diagnosis or reporting. Finally, 
postmortem examinations to confirm prostate cancer 
diagnoses were performed only in certain cases based 
on the decision of the primary physician.
Conclusion
Overall, there was an increasing trend in mortality 
rate and YLL due to prostate cancer in Yazd Province 
between 2001–2010. Moreover, the incidence of 
prostate cancer is expected to rise further in the near 
future due to increasing life expectancy. As such, the 
national healthcare system in Iran should develop 
specifically targeted plans for the prevention and 
management of various diseases, particularly those 
more prevalent among the elderly, such as prostate 
cancer. Early prostate cancer screening programmes 
should be developed and healthy diet and lifestyle 
choices should be promoted among the general 
population. However, in order to implement these 
measures successfully, further studies are needed to 
investigate the effectiveness of various methods for 
reversing the rising trend of prostate cancer. 
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